John Lepore, MD joined Flagship Pioneering in 2023 as CEO-Partner and Chief Executive Officer of ProFound Therapeutics.
John was previously Senior Vice President, Head of Research at GSK, where he led a large organization of scientists and physicians focused on leveraging the science of immunology, human genetics and genomics, and advanced technologies to identify novel drug targets, discover new therapeutic molecules, and demonstrate proof of mechanism in clinical studies.
During his 17-year tenure at GSK, he held roles of increasing responsibility including VP of Clinical Pharmacology and Discovery Medicine, VP and Head of the Heart Failure Discovery Performance Unit, SVP and Head of the Metabolic Pathways and Cardiovascular Therapeutic Area Unit, and SVP R&D Pipeline responsible for end-to-end R&D activities across multiple therapeutic areas. He was also Interim Head of Business Development and played a key role in multiple preclinical and clinical deals to augment the GSK pipeline.
Before joining GSK, John was on the faculty of the cardiovascular medicine division of the department of medicine at the University of Pennsylvania, where his lab investigated the transcriptional regulation of cardiovascular development, and he was attending physician on the academic cardiology service.
John received his BS in biology from the University of Scranton and his medical degree from Harvard Medical School, where he was a Howard Hughes Medical Institute Research Scholar. He subsequently trained in internal medicine and cardiology at Massachusetts General Hospital with post-doctoral training at the Harvard School of Public Health.